Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.
Vandetanib is an inhibitor of the vascular endothelial growth factor receptor 2 tyrosine kinase and the epidermal growth factor receptor tyrosine kinase, recently used in the treatment of different tumors. We describe a case of a photo-allergic reaction to vandetanib in an 80-year-old Caucasian woman affected by metastatic non-small cell lung cancer. Phototoxic reactions to vandetanib have been rarely reported in the literature. Dermatologists should be aware of this cutaneous side effect of vandetanib treatment and affected patients should be counseled to use adequate sun protection.
Fava
Paolo
P
Department of Biomedical Sciences and Human Oncology, Dermatologic Division, University of Turin, via Cherasco 23, Turin, Italy.
Quaglino
Pietro
P
Fierro
Maria Teresa
MT
Novelli
Mauro
M
Bernengo
Maria Grazia
MG
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017454:Dermatitis, Photoallergic / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D010880:Piperidines; D011799:Quinazolines; D040301:Vascular Endothelial Growth Factor Receptor-2; C452423:vandetanib